Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial

Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahhal, Alaa, Najim, Mostafa, Aljundi, Amer Hussein, Mahfouz, Ahmed, Alyafei, Sumaya Mehdar, Awaisu, Ahmed, Habib, Mhd, Baraa, Obeidat, Ibrahim, Faisal, Mohanad Mohammed, Alanzi, Meshaal Ali, Nair, Arun Prabhakaran, Elhassan, Areeg, Al-Dushain, Abdullah, Abdelmajid, Alaaeldin Abdelmajid, Abdelgader, Ahmed Elfadil, Moursi, Ahmed Mahmoud Ahmed, Alharafsheh, Ahmad Eid Nazzal, Kamar, Mohd Ragheb Abou, Goravey, Wael, Omar, Amr Salah, Abukhattab, Mohammed, Khatib, Mohamad Yahya, Mohamedali, Mohamed Gaafar, AlMaslamani, Muna A. Rahman, Alemadi, Samar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524530/
https://www.ncbi.nlm.nih.gov/pubmed/36181009
http://dx.doi.org/10.1097/MD.0000000000030843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524530/
https://www.ncbi.nlm.nih.gov/pubmed/36181009
http://dx.doi.org/10.1097/MD.0000000000030843

Ejemplares similares